The hydrocephalus shunts market is expected to grow US$ 360.01 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028.
Shunt, the surgical insertion of a drainage system is the most common remedy for hydrocephalus. It drains extra cerebrospinal fluid from the brain to another part of the body such as the abdomen, where it can be more easily absorbed. It consists of a long and flexible tube with a valve that keeps fluid from the brain flowing in the right approach and at the proper rate.
Hydrocephalus is more prevalent in children and infants than adult population worldwide. Additionally, the disease is also prevalent in people aged 60 and above. According to the Hydrocephalus Association, the disease affects over 1 million Americans. Additionally, the incidence rate of hydrocephalus in the US is 1 in every 770 babies.
According to the Hydrocephalus Association, hydrocephalus affects over 1 million Americans. Additionally, the incidence rate of the disease in the US is 1 in every 770 babies. According to the article “Global hydrocephalus epidemiology and incidence: systematic review and meta-analysis,” published in the Journal of Neurosurgery (JNS) in 2019, low-income and middle-income countries, particularly those in Africa and Latin America, experience the most significant burden of hydrocephalus. The article also states that Sub-Saharan Africa witnessed an annual incidence of more than 225,000 new cases of infant hydrocephalus, i.e., 750 new cases per 100,000 live births. Moreover, in a European cohort, the incidence rate was estimated at 110 cases of infantile hydrocephalus per 100,000 live births. The treatment approach of hydrocephalus highly focuses on managing CSF through medical devices named shunts. The shunt systems remove excess cerebrospinal fluid from the brain and divert it to other body parts, wherein it is absorbed as a part of the circulatory process.
Market leaders operating in the market have undertaken various organic growth strategies in the hydrocephalus shunts market. The hydrocephalus shunts market majorly consists of the players including B. Braun Melsungen AG (CHRISTOPH MIETHKE GMBH & CO. KG); Sophysa; HpBio Próteses, inc.; Integra LifeSciences Holdings Corporation; KANEKA MEDIX CORP.; Medtronic; Natus Medical Incorporated; Spiegelberg GmbH & Co. KG; Desu Medical among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.
Below is the list of the growth strategies done by the players operating in the hydrocephalus shunts market:
| Company | Month & Year | Category | Description |
| Medtronic | Feb’21 | Product News | USFDA announced the Class 2 device recall of Medtronic’s Delta CSF Flow Control Valves and Shunts. The reason for the recall was the potential for variation in radiopaque marking visibility under radiographic imaging for adjustable and fixed-pressure valves. |
| B. Braun Melsungen AG | May’20 | Product Launch | Aesculap, Inc. in partnership with The Christoph Miethke GmbH & Co. KG (MIETHKE) announced the launch of the M.blue valve in the US. The M.blue valve features advanced gravitational technology, which is incorporated with a fixed differential pressure unit in one valve. It helps to provide a simple and position-dependent solution. |
| Integra LifeSciences Holdings Corporation | Jul’19 | Mergers and Acquisitions | Integra LifeSciences announced the acquisition of Arkis Biosciences Inc. a privately-held company that offers a portfolio of neurosurgical devices such as catheters. The acquisition of Arkis Biosciences strengthened Integra’s offerings in neurocritical care and Integra’s position as the world leader in advanced catheter technology. |
| B. Braun Melsungen AG | Jan’18 | Joint Venture | Aesculap AG, a subsidiary of B. Braun Melsungen AG, together with Christoph Miethke announced the formation of the joint venture B. Braun Miethke GmbH & Co. KG. |
